ABSTRACT Osteoporosis (OP) is a chronic skeletal disorder characterized by reduced bone mineral density and increased fracture risk, particularly from hip fractures linked to a 20%–24% increased mortality risk within the first year. Current therapies remained inadequate in addressing metabolic drivers, which prompted exploration of novel targets. Fabkin, a recently identified hormonal complex comprising fatty acid‐binding protein 4 (FABP4), nucleoside diphosphate kinase (NDPK), and adenosine kinase (ADK), was implicated in metabolic and inflammatory signaling. It was suggested that Fabkin could promote Ca 2+ influx and the release of inflammatory factors via the PKA pathway. However, its role in bone loss remained unclear. To investigate the role of Fabkin in OP, an ovariectomy (OVX)‐induced murine model was used to simulate estrogen‐deficient osteoporosis. FABP4‐KO mice were generated to disrupt Fabkin formation, and bone microarchitecture was assessed using micro‐CT and histological staining. Osteoclastogenesis assays in vitro were conducted using bone marrow‐derived macrophages (BMDMs) treated with recombinant Fabkin components. Western blotting and RT‐qPCR were performed to analyze key signaling pathways involved in osteoclast differentiation, particularly MAPK and NF‐κB. Immunofluorescence analysis revealed an increase in Fabkin expression in the bone marrow of OVX mice. OVX‐induced osteoporosis was significantly attenuated in FABP4‐KO mice with higher BMD. TRAP staining showed a reduction in osteoclast numbers in FABP4‐KO mice. In vitro, Fabkin treatment significantly enhanced osteoclast differentiation and bone resorption, whereas FABP4 deficiency inhibited osteoclast formation. Molecular analysis revealed that Fabkin promoted osteoclastogenesis via the RANKL‐induced MAPK and NF‐κB signaling pathways. These findings suggested that FABP4 might directly exacerbate osteoclastogenesis by acting as a Fabkin complex instead of a lipid regulator.
Pan et al. (Thu,) studied this question.